Veeva Systems announced that Boehringer Ingelheim has launched its own drug discovery platform, “One Medicine Platform,” through the successful implementation of Veeva Development Cloud.
The two companies announced the One Medicine collaboration in March 2022. Veeva ‘s unified platform will unify data and processes across clinical, regulatory, and quality to help Boehringer streamline clinical development. The One Medicine Platform will enable Boehringer to seamlessly connect data across functions, optimize clinical trial efficiency and research collaboration, and accelerate the delivery of new medicines to treat currently difficult-to-treat diseases.
“Together with Veeva, Boehringer is evolving its approach to clinical trials to deliver on its promise to rapidly bring innovative, life-changing therapies to patients around the world,” said Oliver Fink, head of Learning, Process and Digitalization at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and execute studies more quickly, efficiently, and compliantly.”
“By connecting clinical, regulatory, and quality with Veeva Development Cloud, Boehringer will unify data and break down silos between teams to accelerate drug development and approval,” said Rik van Mol, senior vice president of Veeva Development Cloud. “This marks a milestone in Veeva and Boehringer’s shared mission to accelerate the use of data and technology to modernize clinical trials and improve patient outcomes.”
Veeva Development Cloud is the technology foundation for clinical development, integrating clinical, quality, regulatory, and safety applications to streamline end-to-end business processes and enable process excellence.
SOURCE: PRTimes
